Skip to main content

Advertisement

Table 2 Proxy relative survival (RS) and distribution of the 27 cancer sites (GLOBOCAN 2012)

From: Global comparison of cancer outcomes: standardization and correlation with healthcare expenditures

Cancer sites World population Proportion (%) of new cases among different countries
Proxy RS Proportion (%) of new cases a Range Difference b
Thyroid 0.875 2.1 (0.0, 15.0) 15.0
Testis 0.800 0.4 (0.0, 1.6) 1.6
Corpus uteri 0.780 2.3 (0.0, 6.6) 6.6
Melanoma of skin 0.767 1.7 (0.0, 11.6) 11.6
Prostate 0.745 7.8 (0.6, 42.6) 42.0
Breast 0.701 11.9 (2.8, 26.7) 23.9
Hodgkin lymphoma 0.667 0.5 (0.0, 3.7) 3.7
Bladder 0.642 3.1 (0.2, 8.6) 8.4
Kidney 0.591 2.4 (0.0, 5.7) 5.7
Lip, oral cavity 0.525 2.1 (0.0, 13.6) 13.6
Colorectum 0.517 9.7 (0.7, 17.0) 16.3
Cervix uteri 0.514 3.8 (0.5, 32.7) 32.2
Non-Hodgkin lymphoma 0.500 2.7 (0.4, 12.0) 11.6
Larynx 0.476 1.1 (0.0, 4.1) 4.1
Nasopharynx 0.417 0.6 (0.0, 5.4) 5.4
Ovary 0.393 1.7 (0.4, 5.7) 5.3
Kaposi sarcoma 0.333 0.3 (0.0, 26.2) 26.2
Multiple myeloma 0.333 0.8 (0.0, 2.8) 2.8
Other pharynx 0.316 1.0 (0.0, 8.1) 8.1
Leukaemia 0.277 2.5 (0.0, 10.0) 10.0
Brain, nervous system 0.265 1.8 (0.0, 5.7) 5.7
Stomach 0.264 6.8 (0.5, 20.0) 19.5
Gallbladder 0.227 1.3 (0.0, 5.6) 5.6
Oesophagus 0.153 3.2 (0.0, 12.8) 12.8
Lung 0.147 13.0 (0.4, 25.0) 24.6
Liver 0.059 5.6 (0.5, 42.7) 42.2
Pancreas 0.048 2.4 (0.0, 4.7) 4.7
  1. a Proportion of new cases among all cancers except non-melanoma skin cancer
  2. b Difference in proportion of new cases between the countries with the highest and lowest proportions